natgillin/translations-raw huggingface dataset:
The composition of claim 4, wherein the common carrier is diphtheria toxoid. 
Sastav prema zahtjevu 4, naznačen time da je zajednički nosač difterija toksoid.
The composition of claim 4, wherein the common carrier is Hinfluenzae protein D. 
Sastav prema zahtjevu 4, naznačen time da je zajednički nosač Hinfluenzae protein D.
The composition of any preceding claim, wherein the total concentration of common carrier in the composition is less than 100µg/ml. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da je ukupna koncentracija zajedničkog nosača u sastavu manja od 100 µg/ml.
The composition of any preceding claim, formulated for intramuscular injection. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da je formuliran za intramuskularno injektiranje.
The composition of any preceding claim, wherein the composition does not include any mercurial material. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time da sastav ne uključuje materijale koji sadrže živu.
A syringe containing the composition of any preceding claim. 
Šprica za davanje injekcija, naznačena time da sadrži sastav prema bilo kojem od prethodnih zahtjeva.
A kit for preparing the composition of any one of claims 1 to 15, wherein the kit comprises at least one meningococcal conjugate in lyophilised form and at least one meningococcal conjugate in aqueous form. 
Pribor za pripremu sastava prema bilo kojem od zahtjeva 1 do 15, naznačen time da pribor sadrži najmanje jedan meningokokni konjugat u liofiličnom obliku i najmanje jedan meningokokni konjugat u vodenom obliku.
A kit for preparing the composition of any one of claims 1 to 15, wherein the kit comprises (i) the lyophilised composition of claim 16, and (ii) aqueous material, wherein component (ii) is for reconstituting component (i) in order to provide the aqueous composition. 
Pribor za pripremu sastava prema bilo kojem od zahtjeva 1 do 15, naznačen time da pribor sadrži (i) liofilični sastav prema zahtjevu 16 i (ii) vodeni materijal, pri čemu komponenta (ii) ima ulogu rekonstituiranja komponente (i) kako bi dala vodeni sastav.
A process for preparing a composition for immunising a patient against a disease caused by Neisseria meningitidis, comprising the steps of: 
Postupak za pripremu sastava za imunizaciju pacijenta protiv bolesti uzrkovane Neisseria meningitidisom, naznačen time da sadrži korake:
A process for preparing a composition for immunising a patient against a disease caused by Neisseria meningitidis, comprising the steps of: 
Postupak za pripremu sastava za imunizaciju bolesnika protiv bolesti uzrokovane Neisseria meningitidisom, naznačen time da sadrži korake:
mixing the n conjugates prepared in step (1), to give a composition that includes the common carrier in an unconjugated form, wherein the concentration of the unconjugated common carrier is less than 10 µg/ml. 
miješanje n konjugata pripremljenih u koraku (1), tako da daje sastav koji uključuje zajednički nosač u nekonjugiranom obliku, gdje je koncentracija nekonjugiranog zajedničkog nosača manja od 10 μg/ml.
The process of claim 26, comprising a measurement step before mixing of the conjugates and/or a measurement step after mixing the conjugates. 
Postupak prema zahtjevu 26, naznačen time da sadrži korak mjerenja prije miješanja konjugata i/ili korak mjerenja nakon miješanja konjugata.
free radicals with a deodorisation and sanitation effect being formed by Fenton's reaction, the sludge then being dewatered at a pH of at most 7, and the aqueous solution obtained in dewatering being recirculated to the wastewater purification, characterised in that the sludge is supplied with an amount of 10-100 kg of 100% hydrogen peroxide per tonne of dry solids, if hydrogen peroxide is used as the oxidiser, and the sludge that is treated is made to contain dissolved iron and phosphorus at a molar ratio Fe:P of above 1:1. 
slobodni radikali sa deodorizirajućim i sanitarnim efektom formirani su preko Fenton-ove reakcije, iz mulja se zatim uklanja voda na pH vrijednosti od najviše 7, i vodena otopina koja je dobijena prilikom uklanjanja vode se recirkulira u pročišćavanje otpadne vode, naznačen time što se mulj snabdijeva količinom od 10-100 kg 100% vodikova peroksida po toni suhih čvrstih supstanci, ako se vodikov peroksid koristi kao sredstvo za oksidaciju, i mulj koji se tretira je uređen tako da sadrži otopljeno željezo i fosfor u molarnom odnosu Fe:P od preko 1:1.
A method as claimed in claim 7, characterised in that the sludge is supplied with hydrogen peroxide as an oxidiser in an amount of 30-60 kg, 100% hydrogen peroxide per tonne of dry solids. 
Postupak prema patentnom zahtjevu 7, naznačen time što se mulj snabdijeva vodikovim peroksidom kao sredstvom za oksidaciju u količini od 30-60 kg, 100% vodikova peroksida po toni suhih čvrstih supstanci.
A method as claimed in any one of the preceding claims, characterised in that the sludge is dewatered to a solids content of at least 30% by weight. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što se voda iz mulja uklanja do sadržaja čvrstih supstanci od najmanje 30 tež.%.
A method as claimed in claim 12, characterised in that the sludge is dewatered to a solids content of 35-60% by weight. 
Postupak prema patentnom zahtjevu 12, naznačen time što se voda iz mulja uklanja do sadržaja čvrstih supstanci od 35-60 tež.%.
An isoxazolic derivative of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of neuropathic pain. 
Izoksazolni derivat formule (I) [image] ili njegova farmaceutski prihvatljiva sol, naznačeni time, što se koriste za primjenu u liječenju neuropatskih bolova.
Use of an isoxazolic derivative of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of neuropathic pain. 
Primjena izoksazolnog derivata formule (I) [image] ili njegove farmaceutski prihvatljive soli, naznačena time, što se koristi u proizvodnji lijeka za liječenje neuropatskih bolova.
Compound of formula A for use in treating a KIT dependent disease in a patient, which comprises: 
Spoj, naznačen time, da je formule A [image] za uporabu u liječenju KIT ovisnog oboljenja kod pacijenta, a koja obuhvaća:
Compound according to any of Claims 1-5, wherein the KIT dependent disease is selected from mast cell diseases, acute myelogenous leukemia, gastrointestinal stromal tumors, seminomas and dysgerminomas. 
Spoj u skladu s bilo kojim zahtjevom 1 do 5, naznačen time, da je KIT ovisno oboljenje izabrano između oboljenja mastocita, akutne mijelogene leukemije, gastrointestinalnih stroma tumora, seminoma i disgerminoma.
The isoquinoline derivative of claim 1, wherein X is O, S or NH; 
Izokinolinski derivat u skladu s patentnim zahtjevom 1, gdje X je O, S ili NH;
The isoquinoline derivative of claim 1 or 2, wherein Y is OH. 
Izokinolinski derivat u skladu s patentnim zahtjevom 1 ili 2, gdje Y je OH.
Use of an isoquinoline derivative of any one of claims 1-7 for the preparation of a medicament for the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma. 
Upotreba izokinolinskog derivata u skladu s bilo kojim od patentnih zahtjeva 1 do 7, u pripravi medikamenta za liječenje poremećaja povezanih s ROCK-I, poput hipertenzije, ateroskleroze i glaukoma.
collecting and drying the microparticles formed in step (b) wherein step (b) is carried out by emulsifying the emulsion prepared in step (a) in a coherent aqueous phase to obtain a w/o/w-double emulsion, wherein the coherent aqueous phase comprises an osmotic agent. 
prikupljanje i sušenje mikrodijelova oblikovanih u koraku (b) pri čemu korak (b) se provodi emulzifikacijom emulzije pripremljene u koraku (a) i povezane vodene faze da bi se dobila w/o/w-dvostruka emulzija, pri čemu povezana vodena faza sadrži osmotski agens, pri čemu je osmolalnost povezane vodene faze viša od one vodene unutarnje faze.
lactic acid at 80% solution, to reach pH 8; 
mliječna kiselina u otopini 80 % za ugađanje na vrijednost pH 8;
demineralized water q.s. to 100 g. 
demineralizirana voda q.s. do 100 g.
A is a direct bond; 
A je izravna veza;
and R7 are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, N -methyl- N -propylamino, N -ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R16; 
i R7 su nezavisno izabrani iz vodika, fluora, klora, broma, nitro, cijano, amino, metil, metilamino, etilamino, propilamino, izopropilamino, dimetilamino, N-metil-N-propilamino, N-etilkarbamil, metoksikarbonil, etoksikarbonil, butoksikarbonil, morfolino, pirolidinil ili piperazinila; pri čemu R6 i R7 mogu nezavisno jedan od drugog po mogućnosti biti supstituirani na ugljiku sa jednim ili više R15; te pri čemu spomenuti piperazinil može po mogućnosti biti supstituiran na dušiku sa grupom izabranom iz R16;
is selected from methyl; 
je izabran iz metila;
A compound of formula (I), as claimed in claim 1, selected from: 
Spoj formule (I), prema patentnom zahtjevu 1, izabran iz:
Process a) reaction of a pyrimidine of formula (II): wherein L is a displaceable group; with an pyrazole amine of formula (III): or 
Postupak a) reakcija pirimidina formule (II): [image] gdje je L zamjenjiva grupa; sa pirazol aminom formule (III):
Process b) reacting a pyrimidine of formula (IV): wherein L is a displaceable group; with a compound of formula (V): 
[image] ili Postupak b) reakcija pirimidina formule (IV): [image] gdje je L zamjenjiva grupa; sa spojem formule (V):
converting a compound of the formula (I) into another compound of the formula (I); 
pretvaranje spoja formule (I) u drugi spoj formule (I);
ii) removing any protecting groups; 
ii) uklanjanje zaštitnih grupa;
The use according to claim 12 wherein said cancer is selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposis sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibrosarcoma and osteosarcoma. 
Uporaba prema patentnom zahtjevu 12 naznačena time da je spomenuti rak izabran iz raka jednjaka, mijelome, hepatocelularnog, raka gušteraće, raka crijeva, ewings tumora, neuroblastome, kapozne sarkome, raka jajnika, raka dojke, raka debelog crijeva, raka prostate, raka mjehura, melanome, raka pluća – non small cell lung cancer (NSCLC), small cell lung cancer (SCLC), raka želuca, raka glave i vrata, raka bubrega, limfome, leukemije, tumora centralnog i perifernog živčanog sustava, melanome, fibrosarkome i osteosarkome.
A process for the preparation of vitamin K2 (MK - 7) comprising the culture of Bacillus subtilis mutant strain GN13/72 - DSM 17766 deposited on December O5, 2005 at the DSMZ. 
Postupak priprave vitamina K2 (MK - 7), naznačen time da obuhvaća mutanta kulture Bacillus subtilis soja GN13/72 - DSM 17766 položenog 5. prosinca 2005. u DSMZ.
The process claimed in claim 1 wherein the biomass obtained from the culture is dried by spray-drying. 
Postupak kako je prijavljen u patentnom zahtjevu 1, naznačen time da je biomasa dobivena od kulture sprej-sušena.
A compound of the general formula (I): or an N-oxide thereof, or any of its isomers or any mixture of its isomers, or a pharmaceutical acceptable salt thereof, wherein Ra, Rb and Rc independent of each other represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkyl, arylalkyl, formyl, alkylcarbonyl or alkoxyalkylcarbonyl; 
Spoj opće formule (I): [image] ili njegov N-oksid, ili bilo koji njegov izomer ili bilo koja mješavina njegovih izomera, ili njegova farmaceutski prihvatljiva sol, naznačen time, da Ra, Rb i Rc nezavisno jedan od drugoga svaki predstavlja vodik, alkil, cikloalkil, cikloalkilalkil, alkenil, alkinil, hidroksi, alkoksi, alkoksialkil, arilalkil, formil, alkilkarbonil ili alkoksialkilkarbonil; Rd predstavlja heteroarilnu skupinu;
The use according to claim 8, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the GABAA receptor complex in the central nervous system. 
Uporaba prema zahtjevu 8, naznačena time da je za pripravu farmaceutskog pripravka, za liječenje, prevenciju ili ublažavanje bolesti ili poremećaja ili stanja kod sisavaca, uključujući i čovjeka, pri čemu navedena bolest, poremećaj ili stanje reagira na modulaciju iz GABAA receptorskog kompleksa u središnjem živčanom sustavu.
A dicyclohexylamine salt of compound of formula I, namely perindopril, having an X-ray powder diffraction pattern with characteristic peaks (2θ): 8.462, 10.624, 18.693, 9.424, 17.272, 14.177, 19.499, 20.765, 21.409, and 14.540. 
Dicikloheksilamin sol spoja formule I, odnosno perindoprila, koja ima uzorak difrakcije X-zraka na prahu sa slijedećim karakterističnim signalima (2θ): 8.462, 10.624, 18.693, 9.424, 17.272, 14.177, 19.499, 20.765, 21.409 i 14.540. [image]
A dicyclohexylamine salt of perindopril as claimed in claim 1 having an X-ray diffractogram, or substantially the same X-ray diffractogram, as set out in Figure 1. 
Dicikloheksilamin sol perindoprila prema zahtjevu 1, koja ima difraktogram X-zraka, ili u biti isti difraktogram X-zraka, kao što je prikazano na slici 1.
A dicyclohexylamine salt of perindopril as claimed in claim 1 having DSC thermogram as described in Fig. 2. 
Dicikloheksilamin sol perindoprila prema zahtjevu 1, koja ima DSC termogram kao što je prikazano na slici 2.
A dicyclohexylamine salt of perindopril as claimed in claim 1 having TGA thermogram as described in Fig. 3. 
Dicikloheksilamin sol perindoprila prema zahtjevu 1, koja ima TGA termogram kao što je prikazano na slici 3.
treating perindopril with dicyclohexylamine in the presence of a solvent to form salt of perindopril with dicyclohexylamine; 
tretiranje perindoprila s dicikloheksilaminom u prisustvu otapala da bi se dobila sol perindoprila s dicikloheksilaminom;
isolating said dicyclohexylamine salt of a compound of formula I; 
izoliranje spomenute dicikloheksilamin soli spoja formule I;
A process for the purification of compound of formula I, namely Perindopril, comprising steps of: 
Postupak pročišćavanja spoja formule I, odnosno perindoprila [image] koji obuhvaća stupnjeve:
converting to dicyclohexylamine salt of compound of formula I with high purity. 
pretvaranje u dicikloheksilamin sol spoja formule I visoke čistoće.
A process for the purification of Perindopril as claimed in claim 5 or 6 wherein in Step(i) the said solvent is acetonitrile. 
Postupak pročišćavanja perindoprila prema zahtjevu 5 ili 6, gdje je u stupnju (i) spomenuto otapalo acetonitril.
A process for the purification of Perindopril as claimed in claim 5 or 6 wherein in Step(iii) the said solvent is selected from the group comprising ketones, alcohols, nitriles, nitroalkane, acetals, ether, aromatic hydrocarbon, chlorinated solvents or mixture thereof. 
Postupak pročišćavanja peridoprila prema zahtjevu 5 ili 6, gdje je u stupnju (iii) spomenuto otapalo izabran iz grupe koju čine ketoni, alkoholi, nitrili, nitroalkani, acetali, eteri, aromatični ugljikvodici, klorirana otapala ili njihova smjesa.
A process for the purification of Perindopril as claimed in claim 5 or 6 wherein in Step(iii) the said solvent is selected from the group comprising acetone, ethanol, acetonitrile, nitromethane, 2,2-dimethoxy propane, diisopropyl ether, toluene, dichloromethane or mixture thereof. 
Postupak pročišćavanja perindoprila prema zahtjevima 5 ili 6, gdje je u stupnju (iii) spomenuto otapalo izabran iz grupe koju čine aceton, etanol, acetonitril, nitrometan, 2,2-dimetoksi propan, diizopropil eter, toluen, diklorometan ili njihova smjesa.
treating Perindopril in a solvent with dicyclohexylamine to form a compound of formula I in the form of a salt with dicyclohexylamine; 
tretiranje perindoprila u otapalu s dicikloheksilaminom da bi se dobio spoj formule I u obliku soli s dicikloheksilaminom;
A process for the purification of Perindopril as claimed in claim 10 wherein in Step(iii) the said acidic agent is hydrochloric acid. 
Postupak pročišćavanja perindoprila prema zahtjevu 10, gdje je u stupnju (iii) spomenuti kiseli reagens klorovodonična kiselina.
A pharmaceutical composition comprising an effective amount of an active ingredient comprising bifeprunox mesylate and at least one pharmaceutically acceptable excipient, 
Farmaceutski sastav naznačen time da se sastoji od učinkovite količine aktivnog sastojka koji čini bifeprunoks mesilat i najmanje jednog farmaceutski prihvatljivog ekscipijenta,
wherein the effective amount of bifeprunox mesylate is about 0.05 to about 40 mg, with the proviso that the effective amount is not 10 mg, and further comprising lactose monohydrate, sodium starch glycolate, sodium stearyl fumarate and microcrystalline cellulose. 
pri čemu učinkovit iznos bifeprunoks mesilata iznosi oko 0.05 do oko 40 mg, s tim da učinkovita količina nije 10 mg, i nadalje da sadrži laktozu monohidrat, natrijev škrobni glikolat, natrij stearil fumarat i mikrokristalnu celulozu.
The pharmaceutical composition of claim 1, wherein the effective amount of bifeprunox mesylate is about 0.125 to about 20 mg. 
Farmaceutski sastav prema zahtjevu 1, naznačen time da učinkovita količina bifeprunoks mesilata iznosi oko 0.125 do oko 20 mg.
The pharmaceutical composition of claim 1, wherein the effective amount of bifeprunox mesylate is 20 mg. 
Farmaceutski sastav prema zahtjevu 1, naznačen time da učinkovita količina bifeprunoks mesilata iznosi 20 mg.
Use of the pharmaceutical composition of any one of claims 1-8 for the preparation of a medicament for the treatment of a CNS disorder, wherein the amount is effective for treatment of the disorder and wherein administration to the patient results in exhibition of at least one of: 
Upotreba farmaceutskog sastava prema bilo kojem od zahtjeva 1-8 za pripremu lijeka za liječenje poremećaja CNS-a, pri čemu je količina djelotvorna za liječenje poremećaja, te davanje pacijentu rezultira sa prikazivanjem najmanje jednog od:
The use according to claim 9, wherein the CNS disorder is chosen from a psychotic disorder and Parkinson's disease. 
Upotreba prema zahtjevu 9, naznačena time da je poremećaj CNS-a izabran iz psihotičnog poremećaja i Parkinsonove bolesti.
a drive mechanism and 
pogonski mehanizam, i
The one or more compounds of claim 11 wherein the proliferative disease is selected from the group consisting of cancer, psoriasis and rheumatoid arthritis. 
Jedan ili više spojeva prema zahtjevu 11, naznačeni time što je proliferativna bolest izabrana iz skupine koju čine kancer, psorijaza i reumatoidni artritis.
A drug delivery device (1) comprising 
Uređaj za primjenu terapije (1) koji sadrži
A system for processing form markings, comprising: an area-array image sensor (206) configured to sense an image (100) of a form that is in free- space; and a processor (212) configured to interpret at least one marking in the image; 
Sustav za obradu oznaka u obrascu naznačen time, da sadrži: senzor (206) plošne slike od nizova (area-array image) konfiguriran tako da očitava sliku (100) obrasca koji je u slobodnom prostoru;
The system of claim 1, wherein each of the at least one marking is interpreted according to its position with respect to the image. 
Sustav prema patentnom zahtjevu 1, naznačen time, da se barem jedna oznaka interpretira u skladu sa svojim položajem s obzirom na sliku.
The system of claim 2, wherein the at least one light source is a light emitting diode. 
Sustav prema patentnom zahtjevu 2, naznačen time, da barem jedan izvor svjetlosti jest dioda koja emitira svjetlost.
the processor is configured to correctly interpret the at least one marking upon a condition that the form is placed in one of (a) the predetermined position and (b) in any of a plurality of positions that are proximal by a predetermined amount to the predetermined position; and the predetermined amount is based on an amount of space between markings of the form. 
Sustav prema patentnom zahtjevu 2, naznačen time, da je procesor konfiguriran tako da ispravno interpretira barem jednu oznaku, pod uvjetom da je obrazac namješten (a) u jednom od predodređenih položaja i (b) u bilo kojem od više položaja koji se predodređenom veličinom približavaju predodređenom položaju; i predodređena veličina bazirana je na veličini razmaka između oznaka obrasca.
The system of claim 2, wherein the processor is configured to rotate the image to a predetermined orientation before the interpretation of the at least one marking: 
Sustav prema patentnom zahtjevu 2, naznačen time, da je procesor konfiguriran tako da rotira sliku do predodređene orijentacije prije interpretacije barem jedne oznake.
The system of claim 6, wherein: the form includes a first alignment mark in a vicinity of a first edge of the form and a second alignment mark in a vicinity of a second edge of the form; and 
Sustav prema patentnom zahtjevu 6, naznačen time, da obrazac uključuje prvu oznaku poravnanja u blizini prvog ruba obrasca i drugu oznaku poravnanja u blizini drugog ruba obrasca; i procesor rotira obrazac u skladu s prvom i drugom oznakom poravnanja.
The system of claim 8, wherein the area-array image sensor is a complementary metal oxide semiconductor (CMOS). 
Sustav prema patentnom zahtjevu 8, naznačen time, da senzor plošne slike od nizova jest komplementarni metal oksidni poluvodič (CMOS - Complementary metal oxide semiconductor).
The system of claim 1, wherein the processor is configured to interpret the at least one marking as a set of numbers for a lottery drawing entry. 
Sustav prema patentnom zahtjevu 1, naznačen time, da je procesor konfiguriran tako da interpretira barem jednu oznaku kao brojčani niz za unos kod lutrijskog izvlačenja.
The system of claim 1, wherein the image sensor is configured to simultaneously sense a plurality of image lines that, when joined, form the image, and wherein the plurality of image lines includes a first line having first features and a second line having second features different than the first features. 
Sustav prema patentnom zahtjevu 1, naznačen time, da je senzor slike konfiguriran tako da istovremeno očitava više linija slike, da kada su povezane, oblikuju sliku, i u čemu veći broj linija slike uključuje prvu liniju koja ima prve značajke i drugu liniju koja ima druge značajke, različite od prvih značajki.
a camera which includes the image sensor; and a processor configured to interpret at least one marking in the image. 
kameru koja uključuje senzor slike i procesor, konfiguriran tako da interpretira barem jednu oznaku na slici.
The system of claim 1, adapted as a lottery terminal. 
Sustav prema patentnom zahtjevu 1, naznačen time, da je prilagođen kao lutrijski terminal.
a camera that includes the area-array image sensor configured to sense an image of a lottery playslip that is in free-space; and 
kameru koja uključuje senzor plošne slike od nizova, konfiguriran tako da očitava sliku lutrijskog listića koji je u slobodnom prostoru;
A method of inspecting and sorting molded containers, including the steps of: 
Postupak pregledavanja i sortiranja oblikovanih spremnika, koji se sastoji u koracima:
inspecting molded containers for commercial variations outside of acceptable limits, which commercial variations are associated with the mold cavities that produced the containers; 
pregledavanja oblikovanih spremnika na komercijalne varijacije koje izlaze iz prihvatljivih okvira, gdje navedene komercijalne varijacije su povezane sa šupljinama kalupa za proizvodnju spremnika;